Head to Head Contrast: Humacyte (NASDAQ:HUMA) vs. uniQure (NASDAQ:QURE)

uniQure (NASDAQ:QURE) and Humacyte (NASDAQ:HUMA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

Risk & Volatility

uniQure has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, Humacyte has a beta of 2.45, meaning that its stock price is 145% more volatile than the S&P 500.

Profitability

This table compares uniQure and Humacyte’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
uniQure	-1,350.73%	-111.96%	-29.01%
Humacyte	-4,556.29%	-983.32%	-88.84%

Insider and Institutional Ownership

78.8% of uniQure shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 4.7% of uniQure shares are owned by insiders. Comparatively, 3.1% of Humacyte shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for uniQure and Humacyte, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	1	2	14	0	2.76
Humacyte	1	0	6	0	2.71

uniQure currently has a consensus price target of $65.00, suggesting a potential upside of 46.17%. Humacyte has a consensus price target of $6.54, suggesting a potential upside of 1,053.53%. Given Humacyte’s higher possible upside, analysts plainly believe Humacyte is more favorable than uniQure.

Valuation and Earnings

This table compares uniQure and Humacyte”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$16.10 million	191.61	-$198.97 million	($4.01)	-11.09
Humacyte	$2.04 million	77.23	-$40.83 million	($0.49)	-1.16

Humacyte has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Summary

uniQure beats Humacyte on 9 of the 14 factors compared between the two stocks.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

About Humacyte

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.